Scientists from the Institute of Molecular and Cell Biology (IMCB) have identified a new method to target and inhibit telomerase, an enzyme associated with 95 per cent of human cancers, said a report from biotechin.asia.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
